New sources

Latest longevity sources, translated

Brief original commentary on new source material. We summarize, explain why it matters and link out; we do not republish full articles.

55 new sources

Journal of Cachexia, Sarcopenia and Muscle

Nov 15, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: A systematic review of the effect of semaglutide on lean mass

Review context for interpreting lean-mass changes during semaglutide-supported weight loss.

This source is part of LHN's longevity drugs evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Aesthetic Surgery Journal

Nov 15, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: The Clinical Applications of Low-Level Light Therapy

Review context for photobiomodulation and low-level light therapy claims.

This source is part of LHN's mitochondrial health evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Clinics in Laboratory Medicine

Nov 15, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: Organic acid analysis in the clinical laboratory

Clinical-laboratory context for organic acid analysis and why test interpretation depends on indication and method.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Ageing Research Reviews

Nov 15, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence

Systematic review of NAD supplementation evidence across preclinical and clinical work.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Journals of Gerontology: Series A

Nov 14, 2026

Evidence:Human trial evidenceRisk:Lower riskStatus:Status unclear

Source brief: MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of beta-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults

Human trial evidence that a specific NMN formulation can increase circulating NAD-related measures.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Antioxidants & Redox Signaling

Nov 14, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: NAD+ Precursors in Human Health and Disease: Current Status and Future Prospects

Review of NAD precursor biology, human health relevance and unresolved questions.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Gerontology

Nov 13, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: Klotho and Aging: A Mini-Review

Review context for why Klotho appears in longevity and gene-therapy discussions.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Nature Aging

Nov 13, 2026

Evidence:Human observational evidenceRisk:Lower riskStatus:Status unclear

Source brief: Longitudinal changes in epigenetic clocks predict survival in the InCHIANTI cohort

Observational evidence linking longitudinal epigenetic-clock changes with survival in a cohort.

This source is part of LHN's biological age evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Journal of Clinical Medicine

Nov 12, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: The Oxygen Imperative: Cardiorespiratory Fitness, Dose-Dependent Exercise Thresholds, and Longevity-A Narrative Review

Review connecting cardiorespiratory fitness and longevity-oriented outcomes.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

WADA

Nov 12, 2026

Evidence:Regulatory watchRisk:Lower riskStatus:Status unclear

Source brief: WADA Prohibited List

Official anti-doping source for prohibited classes, including unapproved substances and peptide-related categories.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Clinical Epigenetics

Nov 12, 2026

Evidence:Human observational evidenceRisk:Lower riskStatus:Status unclear

Source brief: Association between pace of aging estimated from blood DNA methylation and all-cause mortality: the HUNT study

Cohort evidence connecting a DNA-methylation pace-of-aging measure with mortality.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Aesthetic Surgery Journal

Nov 11, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: The Clinical Applications of Low-Level Light Therapy

Review context for photobiomodulation and low-level light therapy claims.

This source is part of LHN's mitochondrial health evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Clinics in Laboratory Medicine

Nov 11, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: Organic acid analysis in the clinical laboratory

Clinical-laboratory context for organic acid analysis and why test interpretation depends on indication and method.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Journal of Cachexia, Sarcopenia and Muscle

Nov 11, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis

Systematic review/meta-analysis of NMN and NR effects on skeletal muscle outcomes.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Ageing Research Reviews

Nov 10, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence

Systematic review of NAD supplementation evidence across preclinical and clinical work.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Antioxidants & Redox Signaling

Nov 10, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: NAD+ Precursors in Human Health and Disease: Current Status and Future Prospects

Review of NAD precursor biology, human health relevance and unresolved questions.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Gerontology

Nov 9, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: Klotho and Aging: A Mini-Review

Review context for why Klotho appears in longevity and gene-therapy discussions.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Journals of Gerontology: Series A

Nov 9, 2026

Evidence:Human trial evidenceRisk:Lower riskStatus:Status unclear

Source brief: MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of beta-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults

Human trial evidence that a specific NMN formulation can increase circulating NAD-related measures.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Nature Aging

Nov 9, 2026

Evidence:Human observational evidenceRisk:Lower riskStatus:Status unclear

Source brief: Longitudinal changes in epigenetic clocks predict survival in the InCHIANTI cohort

Observational evidence linking longitudinal epigenetic-clock changes with survival in a cohort.

This source is part of LHN's biological age evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Clinical Epigenetics

Nov 8, 2026

Evidence:Human observational evidenceRisk:Lower riskStatus:Status unclear

Source brief: Association between pace of aging estimated from blood DNA methylation and all-cause mortality: the HUNT study

Cohort evidence connecting a DNA-methylation pace-of-aging measure with mortality.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

WADA

Nov 8, 2026

Evidence:Regulatory watchRisk:Lower riskStatus:Status unclear

Source brief: WADA Prohibited List

Official anti-doping source for prohibited classes, including unapproved substances and peptide-related categories.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Journal of Cachexia, Sarcopenia and Muscle

Nov 7, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis

Systematic review/meta-analysis of NMN and NR effects on skeletal muscle outcomes.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Aesthetic Surgery Journal

Nov 7, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: The Clinical Applications of Low-Level Light Therapy

Review context for photobiomodulation and low-level light therapy claims.

This source is part of LHN's mitochondrial health evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Journal of Clinical Medicine

Nov 7, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: The Oxygen Imperative: Cardiorespiratory Fitness, Dose-Dependent Exercise Thresholds, and Longevity-A Narrative Review

Review connecting cardiorespiratory fitness and longevity-oriented outcomes.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Ageing Research Reviews

Nov 6, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence

Systematic review of NAD supplementation evidence across preclinical and clinical work.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Clinics in Laboratory Medicine

Nov 6, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: Organic acid analysis in the clinical laboratory

Clinical-laboratory context for organic acid analysis and why test interpretation depends on indication and method.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Antioxidants & Redox Signaling

Nov 6, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: NAD+ Precursors in Human Health and Disease: Current Status and Future Prospects

Review of NAD precursor biology, human health relevance and unresolved questions.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Nature Aging

Nov 5, 2026

Evidence:Human observational evidenceRisk:Lower riskStatus:Status unclear

Source brief: Longitudinal changes in epigenetic clocks predict survival in the InCHIANTI cohort

Observational evidence linking longitudinal epigenetic-clock changes with survival in a cohort.

This source is part of LHN's biological age evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Journals of Gerontology: Series A

Nov 5, 2026

Evidence:Human trial evidenceRisk:Lower riskStatus:Status unclear

Source brief: MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of beta-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults

Human trial evidence that a specific NMN formulation can increase circulating NAD-related measures.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Gerontology

Nov 4, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: Klotho and Aging: A Mini-Review

Review context for why Klotho appears in longevity and gene-therapy discussions.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Clinical Epigenetics

Nov 4, 2026

Evidence:Human observational evidenceRisk:Lower riskStatus:Status unclear

Source brief: Association between pace of aging estimated from blood DNA methylation and all-cause mortality: the HUNT study

Cohort evidence connecting a DNA-methylation pace-of-aging measure with mortality.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Journal of Cachexia, Sarcopenia and Muscle

Nov 3, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis

Systematic review/meta-analysis of NMN and NR effects on skeletal muscle outcomes.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

WADA

Nov 3, 2026

Evidence:Regulatory watchRisk:Lower riskStatus:Status unclear

Source brief: WADA Prohibited List

Official anti-doping source for prohibited classes, including unapproved substances and peptide-related categories.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Journal of Clinical Medicine

Nov 3, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: The Oxygen Imperative: Cardiorespiratory Fitness, Dose-Dependent Exercise Thresholds, and Longevity-A Narrative Review

Review connecting cardiorespiratory fitness and longevity-oriented outcomes.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Aesthetic Surgery Journal

Nov 2, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: The Clinical Applications of Low-Level Light Therapy

Review context for photobiomodulation and low-level light therapy claims.

This source is part of LHN's mitochondrial health evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Ageing Research Reviews

Nov 2, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence

Systematic review of NAD supplementation evidence across preclinical and clinical work.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Clinics in Laboratory Medicine

Nov 2, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: Organic acid analysis in the clinical laboratory

Clinical-laboratory context for organic acid analysis and why test interpretation depends on indication and method.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Antioxidants & Redox Signaling

Nov 1, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: NAD+ Precursors in Human Health and Disease: Current Status and Future Prospects

Review of NAD precursor biology, human health relevance and unresolved questions.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Journals of Gerontology: Series A

Nov 1, 2026

Evidence:Human trial evidenceRisk:Lower riskStatus:Status unclear

Source brief: MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of beta-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults

Human trial evidence that a specific NMN formulation can increase circulating NAD-related measures.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Gerontology

Oct 31, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: Klotho and Aging: A Mini-Review

Review context for why Klotho appears in longevity and gene-therapy discussions.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Nature Aging

Oct 31, 2026

Evidence:Human observational evidenceRisk:Lower riskStatus:Status unclear

Source brief: Longitudinal changes in epigenetic clocks predict survival in the InCHIANTI cohort

Observational evidence linking longitudinal epigenetic-clock changes with survival in a cohort.

This source is part of LHN's biological age evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Clinical Epigenetics

Oct 30, 2026

Evidence:Human observational evidenceRisk:Lower riskStatus:Status unclear

Source brief: Association between pace of aging estimated from blood DNA methylation and all-cause mortality: the HUNT study

Cohort evidence connecting a DNA-methylation pace-of-aging measure with mortality.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Journal of Clinical Medicine

Oct 30, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: The Oxygen Imperative: Cardiorespiratory Fitness, Dose-Dependent Exercise Thresholds, and Longevity-A Narrative Review

Review connecting cardiorespiratory fitness and longevity-oriented outcomes.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

WADA

Oct 30, 2026

Evidence:Regulatory watchRisk:Lower riskStatus:Status unclear

Source brief: WADA Prohibited List

Official anti-doping source for prohibited classes, including unapproved substances and peptide-related categories.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Journal of Cachexia, Sarcopenia and Muscle

Oct 29, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis

Systematic review/meta-analysis of NMN and NR effects on skeletal muscle outcomes.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Clinics in Laboratory Medicine

Oct 29, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: Organic acid analysis in the clinical laboratory

Clinical-laboratory context for organic acid analysis and why test interpretation depends on indication and method.

This source is part of LHN's general longevity evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Aesthetic Surgery Journal

Oct 29, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: The Clinical Applications of Low-Level Light Therapy

Review context for photobiomodulation and low-level light therapy claims.

This source is part of LHN's mitochondrial health evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Ageing Research Reviews

Oct 28, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence

Systematic review of NAD supplementation evidence across preclinical and clinical work.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Antioxidants & Redox Signaling

Oct 28, 2026

Evidence:Evidence unclearRisk:Lower riskStatus:Status unclear

Source brief: NAD+ Precursors in Human Health and Disease: Current Status and Future Prospects

Review of NAD precursor biology, human health relevance and unresolved questions.

This source is part of LHN's nad and supplements evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

Nature Aging

Oct 27, 2026

Evidence:Human observational evidenceRisk:Lower riskStatus:Status unclear

Source brief: Longitudinal changes in epigenetic clocks predict survival in the InCHIANTI cohort

Observational evidence linking longitudinal epigenetic-clock changes with survival in a cohort.

This source is part of LHN's biological age evidence trail. Reading the original helps separate what the source actually addresses from broader online claims.

Read LHN source brief Original source

FDA

Jun 27, 2026

Evidence:Regulatory watchRisk:Moderate riskStatus:Status unclear

FDA compounding pages remain the first stop for peptide status checks

Peptide claims should be checked against official FDA compounding and approval resources before any clinical inference.

This is a regulatory signal, not efficacy evidence. It helps classify what a clinic or compounder may claim.

Original source LHN briefing

ClinicalTrials.gov

Jun 27, 2026

Evidence:Trial registeredRisk:High riskStatus:Off-label

Rapamycin longevity claims should be mapped to registered human endpoints

Registry searches help distinguish actual human study questions from podcast-level certainty.

A registered trial is stronger than anecdote, but interpretation depends on design, outcomes and reporting.

Original source LHN briefing

FDA

Jun 27, 2026

Evidence:Regulatory watchRisk:ExperimentalStatus:Experimental

FDA-approved gene therapies are disease-specific, not general age-reversal products

The FDA approved-product list is the anchor for separating real gene therapy products from consumer rejuvenation claims.

Approved products can validate a platform category while still saying nothing about broad anti-aging offers.

Original source LHN briefing

PubMed

Jun 27, 2026

Evidence:Human trial evidenceRisk:Moderate riskStatus:Supplement status

NAD precursor studies still need outcome context

Human NAD precursor papers often report biomarker changes, tolerability or small functional measures.

Those signals can be useful, but they are not the same as proven aging modification.

Original source LHN briefing

PubMed

Jun 27, 2026

Evidence:Human observational evidenceRisk:Lower riskStatus:Status unclear

Biological age tests need validation, repeatability and clinical context

Epigenetic clocks are not interchangeable, and individual actionability depends on the model and decision.

A clean AI answer should not compress all clocks into one consumer score.

Original source LHN briefing